Figure 6. Seizure freedom rate at 3 months, 6 months, 12 months and at last visit in patients treated with eslicarbazepine acetate ≤1200mg daily versus >1200mg daily. Seizure freedom was defined as no seizures since at least the prior visit. Statistical comparisons were conducted using the Chi-squared test. Reproduced with permission from Eisai